TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00635791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given by mouth
Study: NCT00761579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Paliperidone oral tablet was administered once daily at a starting dose of either 3 milligram (mg), 6 mg or 9 mg for 48 weeks, wherein recommended dose was 6 mg and dose range was 3 to 12 mg per day.
Study: NCT00877110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8
Description: Patients will receive combination chemotherapy with intravenous (IV) cyclophosphamide 70mg/kg/day (for patients with body weight\<70kg) or 2100mg/m2/day (for patients with body weight ≥70kg) for two days, IV vincristine 0.067mg/kg or 2mg/m2/day (lower of the two doses to be chosen; maximum 2mg) for one day, and IV topotecan 2.4 mg/m2/day for 3 days during their first cycle. If receiving a second and/or third cycle, the only chemotherapy patients will receive is cyclophosphamide at 50 mg/kg/day for 2 days. On Day 0, patients will receive a single dose of allogeneic NK cells isolated from a HLA-haploidentical related donor. On day +3, the patient will start daily infusion of 3F8 for 5 days. The treatment schedule may require minor adjustment by ±1 day as clinically indicated (e.g. due to PDH closure for holidays or due to inclement weather).
Study: NCT02672280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Collagen Membrane with MSC

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medical Collagen Membrane
Study: NCT01310881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSI-189 Phosphate
Description: Once daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSI-189 Phosphate
Description: Once daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSI-189 Phosphate
Description: Once daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSI-189 Phosphate
Description: Once daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSI-189 Phosphate
Description: Once daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSI-189 Phosphate
Description: Once daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSI-189 Phosphate
Description: Once daily oral administration
Study: NCT04512170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585
Description: single or Mulltiple doses up to 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585
Description: single or Mulltiple doses up to 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585
Description: single or Mulltiple doses up to 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585
Description: single or Mulltiple doses up to 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585
Description: single or Mulltiple doses up to 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585
Description: single or Mulltiple doses up to 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: single or Mulltiple doses up to 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: single or Mulltiple doses up to 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: single or Mulltiple doses up to 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: single or Mulltiple doses up to 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: single or Mulltiple doses up to 10 days
Study: NCT04446572

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius CECT5713
Description: Starting at day 0, women of the RA and INF groups consumed (oral route) a daily sachet with \~50 mg of freeze-dried probiotic (\~9 log10 CFU of L. salivarius CECT5713) for 6 months or until a diagnosis of pregnancy (whatever happened first).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius CECT5713
Description: Starting at day 0, women of the RA and INF groups consumed (oral route) a daily sachet with \~50 mg of freeze-dried probiotic (\~9 log10 CFU of L. salivarius CECT5713) for 6 months or until a diagnosis of pregnancy (whatever happened first).
Study: NCT01025154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Induction Cycle: 20 mg/m\^2 IV over approximately 1 hour daily for 5 days (days 1-5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Induction Cycle: 10 mg/m\^2 IV over approximately 30 minutes daily for 3 days (days 1-3), following clofarabine by 1 to 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction Cycle: 1 g/m\^2 IV over approximately 2 hours daily for 5 days (days 1-5), follow clofarabine by 3 to 6 hours.
Study: NCT01810432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat Meal
Description: Administered orally, at breakfast.
Study: NCT02586051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab 1000 milligrams (mg) IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab 1000 milligrams (mg) IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin
Description: High dose (2 grams per kilogram \[g/kg\]) IVIG (maximum 140 grams).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin
Description: High dose (2 grams per kilogram \[g/kg\]) IVIG (maximum 140 grams).
Study: NCT01995630

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMO Tecnis ZA9003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMO Tecnis ZA9003

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMO Sensar AR40e

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMO Sensar AR40e
Study: NCT01431131

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrasocket graft
Description: Intrasocket mineralized cancellous allograft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrasocket plus facial overlay graft
Description: Intrasocket mineralized cancellous allograft plus a facial overlay graft of bovine xenograft
Study: NCT03111173

Intervention type: DEVICE
Group type: OTHER
Intervention: Holter Device
Description: MyECG E3.80 Holter Recorder
Study: NCT00968318

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Excision of strip of deep fascia
Description: operative technique to excise deep fascia.
Study: NCT01455831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin
Description: The experimental arm will receive a subcutaneous injection of 4,500 IU of tinzaparin daily beginning at randomization and continued for 56 days following resection. There will be a minimum of one dose of pre-operative LMWH since it is not reasonable to delay surgery for the purpose of administering LMWH. The maximum duration of pre-operative LMWH will be 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinzaparin
Description: The control arm will receive a daily subcutaneous injection of 4,500 IU of tinzaparin beginning with the first post-operative dose and continued for the duration of hospitalization.
Study: NCT01969890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF administration
Description: Zarzio - 5 microg/kg bis in die for 6 days
Study: NCT01358916

Intervention type: OTHER
Group type: OTHER
Intervention: Mailing of antibiotic therapy guidelines to the sentinel physicians
Description: Mailing of antibiotic therapy guidelines to the sentinel physicians and regular feedback on antibiotic prescription
Study: NCT03737669

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mirasol-treated Fresh Whole Blood
Description: Standard issue FWB, which gave negative serological assay results for HIV, HBV, HCV, and syphilis will subsequently be treated with Mirasol PRT, then stored at 1 - 6 degrees Celsius and transfused within 21 days of collection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Fresh Whole Blood
Description: Fresh whole blood that gave negative serological assay results for HIV, HBV, HCV, and syphilis will be stored at 1 - 6 degrees Celsius and transfused within 21 days of collection.
Study: NCT01387490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Scheduled Telephone Support (ISTS)
Description: ISTS is a telephone intervention that provides injury-related education, training in problem solving, and focused behavioral strategies for problems (e.g., anxiety, depression) that commonly co-occur with Mild Traumatic Brain Injury (MTBI). ISTS also includes access to usual care and web-based and printed educational material. The 12 phone calls included in ISTS will be administered over a 6-month period.
Study: NCT03743610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated altitude
Description: Participants will exercise in simulated altitude will range between 2100 feet and 16400 feet and will increase according to arm guidelines
Study: NCT01387490

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care (UC)
Description: UC is the usual care provided to service members attending the Traumatic Brain Injury (TBI) Clinics at Madigan Army Medical Center and Womack Army Medical Center, plus web-based education and 12 mailings of educational materials over a 6-month period.
Study: NCT04238624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Participants will receive dabrafenib 150 mg orally twice a day
Study: NCT03743610

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simulated altitude
Description: Participants will exercise in simulated altitude will range between 2100 feet and 16400 feet and will increase according to arm guidelines
Study: NCT04238624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Participants will receive trametinib 2 mg orally once a day
Study: NCT06572462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: individualized ATG dosing strategy
Description: Investigators quantified active ATG exposure in 106 haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) recipients, who received a conventional fixed dose of 10 mg/kg ATG during conditioning, the optimal concentration range of active ATG-AUC was determined through the application of machine learning methods, was found to be 100-148.5 × 10\^3 UE·d/L. This concentration range was associated with a reduction in CMV/EBV reactivation, without an increase in acute GVHD or malignant disease relapse. Mathematical function was then exploited to determine the total targeted ATG dose on -3days to -2days based on concentrations of active ATG on -5daysto -4days. Based on this function, investigators established a dosing strategy that aimed to maintain the active ATG-AUC within the optimal range.
Study: NCT03679546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab : The treatment is infused at a dose of 5 mg/kg at week 0, 2 and 6 and then every 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab Injection
Description: Vedolizumab : The treatment is infused at a dose of 300 mg at week 0, 2 and 6 and then every 8 weeks.
Study: NCT01144949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: silodosin
Description: one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one placebo capsule orally, once daily, with food for up to 4 weeks
Study: NCT04550650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training groupe
Description: Using virtual training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF
Description: PNF technique was used

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinning grp
Description: They only worked with spinning bikes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance
Description: Balance development was done
Study: NCT02008292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physostigmine
Description: All subjects will receive physostigmine to induce elevated ACh levels in the brain.
Study: NCT00088465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular olanzapine depot
Description: 45-405 milligram (mg), intramuscular injection, on a 2-, 3-, or 4-week interval.
Study: NCT00495469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189075
Description: GSK189075 is available as a white, capsule-shaped tablet dosage form containing 50mg, 125mg, 250mg or 500mg of GSK189075 per tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Available as Placebo matching tablet to GSK189075
Study: NCT01390857

Intervention type: DRUG
Intervention: Valaciclovir
Study: NCT04138628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: The study drug will be given according to current recommendations as systemic treatment every third week for 12 months or until progression. Treatment will be initiated within 28 days of detection of ctDNA.
Study: NCT01123161

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hypothermia and anti-shivering treatment
Description: Hypothermia is induced using the Celsius Control™ System. Shivering is treated with buspirone, meperidine and surface warming

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group1: IV t-PA and normothermia
Description: Group 1 will t-PA as standard of care and normothermia
Study: NCT03450876

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT04294082

Intervention type: BEHAVIORAL
Intervention: Mindfulness based intervention
Description: A four session, 120 mins per session mindfulness based course delivered weekly oer the course of four weeks. The mindfulness sessions are based on the model delineated by Kabat-Zinn (1992) and will encompass:~* an introduction to mindfulness~* body-scan exercises~* sitting meditation~* mindful movement exercises~* individual and group reflections~* homework exercises
Study: NCT02723851

Intervention type: DEVICE
Intervention: Corsens
Description: Recording and calculating Peak Endocardial Acceleration (PEA) Myocardial Contractility Index \[MCI\] and isovolumetric contraction (IVCT). Measurements will not affect the treatment provided to the patients.

Intervention type: DEVICE
Intervention: Corsens
Description: Recording and calculating Peak Endocardial Acceleration (PEA) Myocardial Contractility Index \[MCI\] and isovolumetric contraction (IVCT). Measurements will not affect the treatment provided to the patients.
Study: NCT02055482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molidustat (BAY85-3934)
Description: BAY85-3934 will be titrated at the scheduled dose control visits to maintain the Hb in the target range of 10.0 to 12.0 g/dL. Available doses include 15, 25, 50, 75, 100, and 150 mg/day OD. Treatment will be for minimum of 6 months to up to a maximum of 36 months.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin
Description: Darbepoetin will be administered according to the local label and titrated at the scheduled dose by intravenous injection. Treatment will be for a minimum of 6 months to up to a maximum of 36 months.
Study: NCT01497444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hypoxia-activated prodrug TH-302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Study: NCT04550156

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colorectal Bundle
Description: 1. Preoperative optimization of the nutritional status: Perform nutritional risk screening (NRS), measure albumin or prealbumin preoperatively and initiate nutritional support~2. Preoperative showering with an antiseptic agent~3. Administer preoperative antibiotic prophylaxis~4. Hair removal in the operative field with clippers~5. Peri-, intra-, and postoperative warming to maintain body temperature~6. Peri- and intraoperative glucose control~7. Usage of a wound protection device~8. Change of gloves and instruments after anastomosis~9. Anastomosis only with experienced senior surgeon present in theatre for any elective and emergency procedures
Study: NCT03743610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated altitude
Description: Participants will exercise in simulated altitude will range between 2100 feet and 16400 feet and will increase according to arm guidelines

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo simulated altitude
Description: Participants will exercise at sea level at similar percentage of intensities to the simulated altitude group.
Study: NCT02571803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary And Lifestyle Counseling
Description: The DASH (Dietary Approaches to Stop Hypertension) diet is a dietary pattern of proven effect on arterial blood pressure reduction. It is rich in fruits, vegetables, whole grains, and low-fat dairy foods; includes meat, fish, poultry, nuts, and beans; and is limited in sugar-sweetened foods and beverages, red meat, and added fats. Dietary counseling will be provided during each of 7 control visits within the 12-month time of observation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimal Medical Treatment
Description: Optimal Medical Treatment as per 2013 ESC Guidelines on the Management of Stable Coronary Artery Disease.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Treatment
Description: Optimal Medical Treatment as per 2013 ESC Guidelines on the Management of Stable Coronary Artery Disease.
Study: NCT03842670

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy
Description: The CBT condition will include 8 weekly, 60-minute sessions, and will be delivered according to the Epstein \& McCrady (2009) cognitive-behavioral treatment manual, excluding material provided in the platform treatment. The treatment manual and accompanying client workbook provide detailed therapist instructions for each session, client exercises, worksheets, and homework assignments. The treatment focuses on cognitive and behavioral coping skills training, and emphasizes problem-solving as an overall approach to dealing with drinking. Treatment sessions may be audio-recorded for supervision and to ensure that the treatment is being delivered as intended.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Relapse Prevention
Description: The MBT condition will be adapted from the 8-week version of the mindfulness-based relapse prevention (MBRP) manual (Bowen et al., 2011; Witkiewitz et al., 2005). The main adaptation will be to eliminate the relapse prevention/CBT components and focus attention on mindfulness practices. The mindfulness practices in MBT are designed to increase awareness of triggers and decrease reactivity to distress or discomfort in the presence of triggers (Witkiewitz \& Bowen, 2010). The relevant worksheets and homework assignments focusing on mindfulness tools will be maintained from the MBRP manual. Treatment sessions may be audio-recorded for supervision and to ensure that the treatment is being delivered as intended.
Study: NCT00590694

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 0.5mg injection monthly according to protocol for one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 0.5mg injection monthly according to protocol for one year
Study: NCT02573285

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simple Aspiration
Description: Aspiration of pneumothorax with a small-bore catheter
Study: NCT02170519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Iloprost
Description: A 20 mcg dose of Iloprost will be given initially.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Iloprost
Description: A 20 mcg dose of Iloprost will be given initially.
Study: NCT03342222

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interference Screws
Description: tibial fixation for ACL reconstruction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interference Screws
Description: tibial fixation for ACL reconstruction
Study: NCT01285232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: 150 mg sc once daily during four weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anakinra
Description: 150 mg sc once daily during four weeks
Study: NCT00835354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefprozil for oral suspension 250 mg/5 mL
Description: 1 x 250 mg/5 mL, single-dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CEFZIL® for Oral Suspension 250 mg/5mL
Description: 1 x 250 mg/5 mL, single-dose fasting
Study: NCT02302222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customizable Dressing with ActiV.A.C. Therapy Unit

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Dressing
Study: NCT03984578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPEOX
Description: Oral Capecitabine: 1000mg/m2 twice a day from Day 1 to 14 of a 3-week cycle, and IV Oxaliplatin: 130mg/m2 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion of 200mg on Day 1 and Day 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine/ 5-FU
Description: Capecitabine: Oral dose of 825mg/m2/day twice a day on radiation days with concurrent radiation median 50.4 Gy/ 28 fractions; or 5-FU: 225mg/m2/day concurrent with radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion of 200mg on Day 1 of each cycle
Study: NCT03095911

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: News items with spin
Description: Interpretation of news items with spin